Research Article
Real-world Data Evaluating Outcomes Following Neoadjuvant and Adjuvant Therapy in Patients with HER2-Positive Early Breast Cancer
Author(s):
Ana-Marija Bukovica Petrc, Marin Golcic, Doris Kolovrat, Tijaha Salopek, Alojzije Kosic, Iva Skocilic, Anita Beg, Sanja Ropac, Maja Kolak and Ivana Mikolasevic
Background: Human Epidermal Growth Factor Receptor (HER2)-positive breast cancer accounts for 15-20% of all breast cancer cases. Despite its biological aggressiveness, it shows high sensitivity to chemotherapy in combination with anti-HER2 therapy. This study aimed to assess the real outcomes of neoadjuvant and adjuvant treatment in patients with HER2 positive early breast cancer in this European region. Methods: A retrospective observational study conducted at the Clinical Hospital Center Rijeka, Croatia included 137 adult patients with histologically confirmed HER2-positive early breast cancer treated between October 2016 and May 2024. HER2 positivity was defined as IHC 3+ or IHC 2+ with a positive FISH result. Primary outcome measures included pathological complete response (pCR) and long-term survival. Results: The median age of t.. Read More»
Select your language of interest to view the total content in your interested language
Annals of Medical and Health Sciences Research received 24805 citations as per google scholar report
The Annals of Medical and Health Sciences Research is a monthly multidisciplinary medical journal.